eplontersen: Clinical Trials

3 completed. 3 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	3	Completed 3
Phase 2	1	Completed 1

Follow eplontersen: new trials by email Literature Review of eplontersen trials Research Report on eplontersen

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers Eplontersen Solution for Injection - Transthyretin-mediated Amyloidosis	Phase 1	Completed	AstraZeneca	12	2024-08-06	2024-11-21
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants Eplontersen, Placebo - Healthy Participants	Phase 1	Completed	Ionis Pharmaceuticals, Inc.	24	2020-04-23	2022-03-31
Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ). ION-682884, Placebo, Vitamin A - Healthy Volunteers, hATTR Amyloidosis	Phase 1 / Phase 2	Completed	Ionis Pharmaceuticals, Inc.	47	2018-12-21	2022-12-19

Sponsors

Ionis Pharmaceuticals, Inc. (2)  ·  AstraZeneca (1)

Countries

Canada (1)  ·  China (1)  ·  United States (1)

Top investigators

Yang Lin, Medical PhD (1)

Results publications

PMID 35869634, PMID 33283485